08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

InSite, Nicox deal

InSite granted Nicox exclusive rights to develop, manufacture and commercialize AzaSite , BromSite and AzaSite Xtra in Europe, the Middle East and Africa. Nicox expects to submit MAAs for AzaSite and BromSite in 1Q16 and...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

InSite, Inspire deal

In June, Akorn Inc. (NASDAQ:AKRX, Lake Forest, Ill.) paid InSite $6 million in exchange for a lower royalty rate that it pays InSite on net sales of ophthalmic product AzaSite azithromycin in North America. Last...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

InSite, Senju deal

InSite granted Senju an exclusive, Japanese license to develop and commercialize InSite's azithromycin ophthalmic solutions using DuraSite sustained drug delivery technology, including macrolide antibiotics AzaSite 1% azithromycin and AzaSite Xtra 2% azithromycin ( ISV-405 )....
07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

InSite, Merck deal

InSite regained North American development rights to AzaSite Xtra 2% azithromycin ophthalmic solution from Inspire Pharmaceuticals Inc. , which Merck acquired in 2011. A joint development committee between InSite and Merck will oversee development and...
08:00 , Mar 3, 2008 |  BioCentury  |  Finance

Ebb & Flow

Ophthalmology company...
00:44 , Feb 26, 2008 |  BC Extra  |  Financial News

InSite raises $60M in note deal

InSite (AMEX:ISV) raised $60 million in a private placement of non-convertible promissory notes due 2019. The notes, which bear 16% interest, are secured by royalties to be paid from U.S. and Canadian sales of AzaSite...